Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/Refractory (R/R) Melanoma

NCT06030037 is registered in ClinicalTrials.gov with Diwakar Davar as lead sponsor.

NCT NCT06030037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06030037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/Refractory (R/R) Melanoma
Lead sponsor
Diwakar Davar
Phase
Phase 2
Overall status
Withdrawn
Start date
March 11, 2025
Completion date
December 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pd-1 refractory advanced melanoma